PureTech Health plc (PRTC.L)
PRTC.L Stock Price Chart
Explore PureTech Health plc interactive price chart. Choose custom timeframes to analyze PRTC.L price movements and trends.
PRTC.L Company Profile
Discover essential business fundamentals and corporate details for PureTech Health plc (PRTC.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jun 2015
Employees
80.00
Website
https://www.puretechhealth.comCEO
Bharatt M. Chowrira
Description
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
PRTC.L Financial Timeline
Browse a chronological timeline of PureTech Health plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 26 Aug 2025
Earnings released on 30 Apr 2025
EPS came in at £0.35 surpassing the estimated -£0.23 by +256.19%, while revenue for the quarter reached £4.03M, missing expectations by -83.32%.
Earnings released on 28 Aug 2024
EPS came in at -£0.12 surpassing the estimated -£0.24 by +48.94%, while revenue for the quarter reached £227.52K, missing expectations by -96.16%.
Earnings released on 25 Apr 2024
EPS came in at -£0.12 surpassing the estimated -£0.26 by +54.02%, while revenue for the quarter reached £142.44K, missing expectations by -96.98%.
Earnings released on 25 Apr 2024
EPS came in at -£0.06, while revenue for the quarter reached £114.72K, missing expectations by -97.57%.
Earnings released on 5 Mar 2024
EPS came in at -£0.06, while revenue for the quarter reached £73.98K.
Earnings released on 29 Aug 2023
EPS came in at -£0.07 falling short of the estimated -£0.00 by -2.91K%, while revenue for the quarter reached £2.49M, missing expectations by -97.11%.
Earnings released on 28 Apr 2023
EPS came in at -£0.06 falling short of the estimated £0.03 by -326.54%, while revenue for the quarter reached £7.00M, beating expectations by +8.54%.
Earnings released on 31 Mar 2023
EPS came in at -£0.04, while revenue for the quarter reached £1.27M.
Earnings released on 30 Sept 2022
EPS came in at -£0.04, while revenue for the quarter reached £3.88M.
Earnings released on 25 Aug 2022
EPS came in at -£0.08 surpassing the estimated -£0.23 by +64.03%, while revenue for the quarter reached £5.79M, missing expectations by -12.82%.
Earnings released on 31 Mar 2022
EPS came in at -£0.04, while revenue for the quarter reached £2.68M.
Earnings released on 31 Dec 2021
EPS came in at £0.04 surpassing the estimated -£0.18 by +121.13%, while revenue for the quarter reached £8.56M, beating expectations by +23.67%.
Earnings released on 30 Sept 2021
EPS came in at £0.02, while revenue for the quarter reached £4.28M.
Earnings released on 30 Jun 2021
EPS came in at -£0.19 falling short of the estimated -£0.17 by -14.13%, while revenue for the quarter reached £4.22M, missing expectations by -10.21%.
Earnings released on 31 Mar 2021
EPS came in at -£0.10, while revenue for the quarter reached £2.11M.
Earnings released on 31 Dec 2020
EPS came in at -£0.30 falling short of the estimated -£0.15 by -106.76%, while revenue for the quarter reached £3.62M, missing expectations by -18.28%.
Earnings released on 30 Sept 2020
EPS came in at -£0.16, while revenue for the quarter reached £1.91M.
PRTC.L Stock Performance
Access detailed PRTC.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.